Tollefsen Douglas M
Division of Hematology, Campus Box 8125, Washington University Medical School, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):454-60. doi: 10.1161/01.ATV.0000256471.22437.88. Epub 2006 Dec 28.
Heparin cofactor II (HCII) has several biochemical properties that distinguish it from other serpins: (1) it specifically inhibits thrombin; (2) the mechanism of inhibition involves binding of an acidic domain in HCII to thrombin exosite I; and (3) the rate of inhibition increases dramatically in the presence of dermatan sulfate molecules having specific structures. Human studies suggest that high plasma HCII levels are protective against in-stent restenosis and atherosclerosis. Studies with HCII knockout mice directly support the hypothesis that HCII interacts with dermatan sulfate in the arterial wall after endothelial injury and thereby exerts an antithrombotic effect. In addition, HCII deficiency appears to promote neointima formation and atherogenesis in mice. These results suggest that HCII plays a unique and important role in vascular homeostasis.
肝素辅因子II(HCII)具有若干使其有别于其他丝氨酸蛋白酶抑制剂的生化特性:(1)它特异性抑制凝血酶;(2)抑制机制涉及HCII中的一个酸性结构域与凝血酶外切位点I结合;(3)在具有特定结构的硫酸皮肤素分子存在的情况下,抑制速率会显著增加。人体研究表明,血浆HCII水平高可预防支架内再狭窄和动脉粥样硬化。对HCII基因敲除小鼠的研究直接支持了以下假说:内皮损伤后,HCII在动脉壁内与硫酸皮肤素相互作用,从而发挥抗血栓作用。此外,HCII缺乏似乎会促进小鼠新生内膜形成和动脉粥样硬化的发生。这些结果表明,HCII在血管稳态中发挥着独特而重要的作用。